Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
KRBP 
Kiromic Biopharma Inc (KRBP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: KRBP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 88.67% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 0.32M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 13667 | Beta 1.66 | 52 Weeks Range 0.05 - 3.31 | Updated Date 04/1/2025 |
52 Weeks Range 0.05 - 3.31 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.17 |
Earnings Date
Report Date 2025-03-17 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -143.47% | Return on Equity (TTM) -1129.81% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 13749417 | Price to Sales(TTM) - |
Enterprise Value 13749417 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.13 | Shares Outstanding 2653480 | Shares Floating 1182229 |
Shares Outstanding 2653480 | Shares Floating 1182229 | ||
Percent Insiders 2.27 | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Kiromic Biopharma Inc
Company Overview
History and Background
Kiromic Biopharma Inc. was founded in 2006. It focuses on developing cell therapies for cancer using its proprietary platforms.
Core Business Areas
- Targeted Immunotherapies: Developing novel immunotherapies that leverage the patient's immune system to fight cancer.
- Alex Platform: Utilizing the ALEX platform to identify and target cancer-specific epitopes.
- Evasins Platform: Harnessing the Evasins platform to evade immune suppression in the tumor microenvironment.
Leadership and Structure
Dr. Maurizio Chiriva-Internati is the CEO. The company has a management team overseeing research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- ALEXIS-ISO-1: Investigational allogeneic CAR-T cell therapy targeting ISO1, currently in clinical trials. Market share is nascent as the product is not yet approved. Competitors include other CAR-T therapy developers such as Novartis (NVS) and Gilead Sciences (GILD).
- ALEXIS-Pro-1: Investigational allogeneic CAR-T cell therapy targeting Pro-1, also in clinical trials. Market share is emerging. Competitors include similar CAR-T developers.
Market Dynamics
Industry Overview
The cell therapy market is rapidly growing, driven by advancements in immuno-oncology and personalized medicine. There's intense competition and high regulatory hurdles.
Positioning
Kiromic Biopharma is positioned as an innovator in the allogeneic CAR-T cell therapy space, focusing on novel targets and platforms to overcome limitations of existing therapies.
Total Addressable Market (TAM)
The global cell therapy market is projected to reach billions of dollars, with significant growth expected in the coming years. Kiromic is targeting specific cancer indications within this broader market.
Upturn SWOT Analysis
Strengths
- Proprietary ALEX and Evasins platforms
- Novel allogeneic CAR-T cell therapy approach
- Experienced leadership team
Weaknesses
- Early-stage clinical development
- Limited financial resources
- Dependence on clinical trial success
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
- Positive clinical trial results
Threats
- Regulatory hurdles and approval delays
- Competition from established CAR-T therapies
- Adverse clinical trial outcomes
Competitors and Market Share
Key Competitors
- NVS
- GILD
- BMY
Competitive Landscape
Kiromic faces intense competition from established pharmaceutical companies with approved CAR-T therapies. Its competitive advantage lies in its proprietary platforms and novel targets.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by preclinical and early clinical development milestones.
Future Projections: Future growth is contingent on successful clinical trials and potential partnerships.
Recent Initiatives: Recent initiatives include advancing clinical trials for ALEXIS-ISO-1 and ALEXIS-Pro-1.
Summary
Kiromic Biopharma is a high-risk, high-reward biotechnology company focused on developing novel cancer immunotherapies. Its proprietary platforms offer potential advantages, but it faces significant challenges in clinical development and competition. Success hinges on positive clinical trial outcomes and securing partnerships. The company's early stage and cash burn are items to watch out for.
Similar Companies
BLUE
Bluebird bio Inc
BLUE
Bluebird bio Inc
CRSP
Crispr Therapeutics AG
CRSP
Crispr Therapeutics AG
EDIT
Editas Medicine Inc
EDIT
Editas Medicine Inc
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
NVS
Novartis AG ADR
NVS
Novartis AG ADR
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data is based on available public information and may not be comprehensive. Market share data are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kiromic Biopharma Inc
Exchange NASDAQ | Headquaters Houston, TX, United States | ||
IPO Launch date 2020-10-16 | CEO & Director Mr. Pietro Bersani CPA, J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 44 | Website https://www.kiromic.com |
Full time employees 44 | Website https://www.kiromic.com | ||
Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, engages in the utilization of non-engineered an engineered allogeneic Gamma Delta T (GDT) cell technologies to develop therapies for solid tumors in the United States. The company's lead product candidate is the Deltacel-01, which is in Phase 1 clinical trial, in combination with low-dose targeted radiation for patients with non-small cell lung cancer. It also develops Isocel, which is clinical trial in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; Procel, which is in clinical trial in combination with low-dose radiation to treat PD-L1 positive solid malignancies; ALEXIS-ISO-1, which is in clinical trial to evaluate Isocel in patients with Mesothelin Isoform 2 positive solid malignancies; and ALEXIS-PRO-1, which is in clinical trial to evaluate Procel in patients with PD-L1 positive solid malignancies. It has a license agreement with Longwood University. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas. On March 21, 2025, Kiromic BioPharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.